Eversept Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-78,987
| Closed | -$11.5M | – | 61 |
|
|
2022
Q2 | $11.5M | Buy |
78,987
+26,116
| +49% | +$3.81M | 0.82% | 30 |
|
|
2022
Q1 | $8.63M | Sell |
52,871
-17,369
| -25% | -$2.84M | 0.66% | 36 |
|
|
2021
Q4 | $11.9M | Buy |
70,240
+11,007
| +19% | +$1.87M | 0.76% | 28 |
|
|
2021
Q3 | $11.2M | Buy |
59,233
+8,097
| +16% | +$1.53M | 0.77% | 32 |
|
|
2021
Q2 | $8.67M | Sell |
51,136
-29,801
| -37% | -$5.05M | 0.58% | 30 |
|
|
2021
Q1 | $11.4M | Buy |
+80,937
| New | +$11.4M | 0.86% | 29 |
|
|
2019
Q4 | – | Sell |
-92,040
| Closed | -$7.4M | – | 68 |
|
|
2019
Q3 | $7.4M | Buy |
92,040
+4,900
| +6% | +$394K | 2.3% | 12 |
|
|
2019
Q2 | $6.32M | Buy |
+87,140
| New | +$6.32M | 1.77% | 16 |
|
|
2018
Q3 | – | Sell |
-63,493
| Closed | -$6.25M | – | 59 |
|
|
2018
Q2 | $6.25M | Sell |
63,493
-15,400
| -20% | -$1.52M | 2.86% | 11 |
|
|
2018
Q1 | $9.4M | Buy |
+78,893
| New | +$9.4M | 4.36% | 7 |
|